2021
438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT)
Schiffer M, Perreault S, McManus D, Ruggero M, Topal J, Seropian S, Bar N. 438 The Efficacy of Measles, Mumps, Rubella (MMR) Vaccination in Multiple Myeloma (MM) Patients after Hematopoietic Stem Cell Transplantation (HSCT). Transplantation And Cellular Therapy 2021, 27: s362-s363. DOI: 10.1016/s2666-6367(21)00464-4.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationMultiple myeloma patientsStem cell transplantationRubella vaccinationMyeloma patientsCell transplantationMumpsPatientsTransplantationVaccinationMeasles
2020
574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation
Schiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.Peer-Reviewed Original ResearchCytokine release syndromeHaploidentical hematopoietic stem cell transplantationHematopoietic stem cell transplantationFebrile neutropeniaHaplo-HSCTStem cell transplantationRelease syndromeBreakthrough infectionsCell transplantationRecurrent feverEmpiric broad-spectrum antibiotic therapyRates of FNBroad-spectrum antibiotic therapyMulti-drug resistant organismsHaplo-HSCT patientsNon-infectious complicationsPost-transplant cyclophosphamideStem cell infusionBlood culture dataPositive blood culturesBroad-spectrum antibioticsYale New Haven HealthBackground FeverAntibacterial prophylaxisSecondary endpoints
2019
2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Perreault S, McManus D, Pulk R, Topal J, Foss F, Isufi I, Seropian S, Bar N. 2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT). Open Forum Infectious Diseases 2019, 6: s947-s947. PMCID: PMC6809600, DOI: 10.1093/ofid/ofz360.2371.Peer-Reviewed Original ResearchAutologous hematopoietic stem cell transplantationHematopoietic stem cell transplantationPost-hematopoietic stem cell transplantationAutologous HSCT patientsAerosolized pentamidinePJP prophylaxisHSCT patientsPJP infectionYear post-hematopoietic stem cell transplantationYale-New Haven HospitalRisk of cytopeniaHigh-dose corticosteroidsStem cell transplantationNew Haven HospitalYears of ageCost of drugsAP prophylaxisDose corticosteroidsJiroveci infectionMonth regimenPrimary endpointRelapsed diseaseSecondary endpointsImmunomodulatory drugsRetrospective study
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategiesMulti-center Observational Characterization of Cytomegalovirus Antiviral Use in Allogenic Hematopoietic Stem-cell Transplantation (HCT) Recipients
Musick W, Vuong N, Aitken S, Liao S, McManus D, Cox J, Perez K, Tichy E, Topal J, Seropian S, Danziger L, Garey K. Multi-center Observational Characterization of Cytomegalovirus Antiviral Use in Allogenic Hematopoietic Stem-cell Transplantation (HCT) Recipients. Open Forum Infectious Diseases 2017, 4: s715-s715. DOI: 10.1093/ofid/ofx163.1922.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationAllogenic hematopoietic stem cell transplantationStem cell transplantationAntiviral use567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT)
Mohamed S, Perreault S, Seropian S, Isufi I, Foss F, Cooper D. 567 Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation (HSCT). Transplantation And Cellular Therapy 2017, 23: s395-s396. DOI: 10.1016/j.bbmt.2016.12.616.Peer-Reviewed Original Research
2015
Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts
Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts. Journal Of Clinical Investigation 2015, 125: 2677-2689. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/jci81229.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdrenal Cortex HormonesAdultAnimalsChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansKaplan-Meier EstimateLeukemiaLymphocyte DepletionMaleMiceMiddle AgedMyelodysplastic SyndromesTissue DonorsT-Lymphocyte SubsetsTransplantation ConditioningTransplantation, HomologousYoung AdultConceptsHematopoietic stem cell transplantationStem cell graftsChronic GVHDT cellsCell graftsT-cell-depleted stem cell graftsPeripheral blood stem cell graftsAllogeneic hematopoietic stem cell transplantationBlood stem cell graftsFunctional T-cell memoryT-cell-replete graftsPathogen-specific T cellsSingle-arm clinical trialT-cell recoveryVirus-specific immunityStem cell allograftsTotal body irradiationMemory T cellsStem cell transplantationT cell memoryAcute leukemia patientsHigh-risk leukemiaNaive T cellsAcute GVHDSevere GVHD
2013
Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation
Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation. Palliative & Supportive Care 2013, 12: 53-61. PMID: 24169207, DOI: 10.1017/s1478951513000552.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultAftercareAgedAnxiety DisordersCooperative BehaviorDepressive DisorderFemaleHematologic NeoplasmsHematopoietic Stem Cell TransplantationHospice and Palliative Care NursingHumansInterdisciplinary CommunicationMaleMass ScreeningMiddle AgedNurse-Patient RelationsNursing AssessmentPatient DischargePatient IsolationProblem SolvingPsychometricsReproducibility of ResultsSick RoleConceptsHematopoietic stem cell transplantationStem cell transplantationCell transplantationHigh-risk hematologic malignanciesPsychological distressNon-malignant diseasesIntense psychological distressHealth care teamOncology patientsStandard treatmentHematologic malignanciesPatient distressCare teamTransplant numbersPatientsTransplantationOverall treatmentMedical issuesDistressFamily membersTreatmentSocial strainRelapseMalignancyDisease
2009
Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia
Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. American Journal Of Hematology 2009, 84: 599-600. PMID: 19650144, DOI: 10.1002/ajh.21478.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaRefractory acute myeloid leukemiaGemtuzumab ozogamicinNonhematologic toxicityMyeloid leukemiaHematopoietic stem cell transplantationGemtuzumab ozogamicin therapySignificant nonhematologic toxicityStem cell transplantationLow response ratePrior regimensSalvage chemotherapyComplete remissionComplete responseCell transplantationToxicity profileDay 1PatientsSingle agentDay 6Grade 1DecitabineOzogamicinRegimenLeukemia
2008
Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.
Maggiore R, Cooper D, Foss F, Shlomchik W, Seropian S. Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High- Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2008, 112: 2216. DOI: 10.1182/blood.v112.11.2216.2216.Peer-Reviewed Original ResearchAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationNon-relapse mortalityUnrelated donor allogeneic hematopoietic stem cell transplantationDonor allogeneic hematopoietic stem cell transplantationKaplan-Meier estimatesStem cell transplantationAcute GVHDSirolimus groupThrombotic microangiopathyOverall survivalHigh-resolution HLA typingAllele-level typingChronic GVHDProphylactic regimenRenal dysfunctionGraft failureDisease recurrenceCell transplantationHLA AHLA-DRB1HLA typingLate-onset acute GvHDPeripheral blood stem cellsLess chronic GVHD